Mayflower Financial Advisors LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Mayflower Financial Advisors LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,427 shares of the biopharmaceutical company's stock, valued at approximately $317,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Algert Global LLC bought a new position in shares of Gilead Sciences in the second quarter worth about $254,000. Creative Planning lifted its holdings in Gilead Sciences by 8.4% during the second quarter. Creative Planning now owns 188,594 shares of the biopharmaceutical company's stock valued at $12,939,000 after purchasing an additional 14,544 shares in the last quarter. Quarry LP bought a new position in shares of Gilead Sciences in the second quarter worth approximately $43,000. B. Riley Wealth Advisors Inc. increased its stake in shares of Gilead Sciences by 25.1% in the second quarter. B. Riley Wealth Advisors Inc. now owns 35,674 shares of the biopharmaceutical company's stock worth $2,448,000 after purchasing an additional 7,155 shares in the last quarter. Finally, SPC Financial Inc. boosted its holdings in Gilead Sciences by 18.2% in the 2nd quarter. SPC Financial Inc. now owns 4,980 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 768 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 1.4 %

Shares of GILD stock traded up $1.36 on Thursday, reaching $96.95. 5,017,406 shares of the company's stock were exchanged, compared to its average volume of 6,704,090. The company's fifty day simple moving average is $92.14 and its 200 day simple moving average is $85.51. The stock has a market capitalization of $120.83 billion, a PE ratio of 1,077.22, a P/E/G ratio of 1.31 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business's revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Morgan Stanley raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Maxim Group lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Finally, Mizuho increased their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.39.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last three months. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.